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(u-PAR, plasminogen receptor) and three inhibitors (plas-
minogen activator inhibitors PAI-1 and PAI-2, protease
nexin 1) (Blasi, 1993).
Pro-uPA binds to its specific cell surface receptor u-
PAR specifically and with high affinity and becomes
cleaved at position 157 by plasmin, which results in the
active two-chain form of u-PA. u-PA can catalyze the ac-
tivation of ubiquitously available plasminogen to plasmin,
which in turn can initiate a proteolytic cascade resulting
in a highly efficient degradation of extracellular matrix
components (Blasi, 1993).
The U-PAR as a Cell Membrane Receptor with
Diverse Functions 
u-PAR is a 55 – 60 kDa, heavily glycosylated cell surface
receptor with a three-domain structure defined by intra-
chain disulfide bonds. It consists of three similar cys-
teine-rich repeats of about 90 amino acids. The amino-
terminal domain 1 is responsible for u-PA binding, while
the other two domains bind vitronectin (Schvartz et al.,
1999). u-PAR is glycosilated at N-residues of glucosa-
mine and sialic acid within the binding site, thereby regu-
lating its affinity (Kd of 0.1 – 1.0 nM) for u-PA (Behrendt
et al.,1990). The carboxy-terminal part of u-PAR is an-
chored to the cell membrane via a glycosyl-phos-
phatidylinositol chain. This GPI-anchor is hypothesized
to enable a high intramembrane mobility (Moller, 1993).
The u-PAR plays an important role in many physiolog-
ical and pathological functions including wound healing,
tissue remodeling, and especially tumor cell invasion and
metastasis. The ability of the u-PAR to promote these bi-
ological effects is a consequence of its diverse functions.
First, receptor-bound uPA, as compared to the fluid
phase enzyme, activates plasminogen to plasmin much
more efficiently, as reflected by a 40-fold decrease in the
Km value of urokinase for its substrate (Ellis et al., 1991).
Plasmin can either directly degrade basement mem-
branes and ECM or activate other proteases. ECM
degradation is a key step in the process of cancer inva-
sion. Second, u-PAR clears urokinase-inhibitor complex-
es from the extracellular space via an α2-macroglobulin
receptor-dependent endocytotic mechanism (Cubellis
et al., 1990; Conese et al., 1994). Third, the u-PAR inter-
acts with the extracellular domain of integrins (Wei et al.,
1996; Yebra et al., 1996). Integrins mediate adhesion of
cells to extracellular matrices as well as intercellular inter-
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The phenomenon of tumor-associated proteolysis
has been acknowledged as a decisive step in the
progression of cancer. This short review focuses on
the urokinase receptor (u-PAR), a central molecule
involved in tumor-associated invasion and metasta-
sis, and summarizes the transcriptional regulation of
u-PAR. The urokinase receptor (u-PAR) is a heavily
glycosylated cell surface protein and binds the serine
protease urokinase specifically and with high affinity.
It consists of three similar cysteine-rich repeats and
is anchored to the cell membrane via a GPI-anchor.
The u-PAR gene comprises 7 exons and is located on
chromosome 19q13. Transcriptional activation of the
u-PAR promoter region can be induced by binding of
transcription factors (Sp1, AP-1, AP-2, NF-B). One
current study gives an example for transcriptional
downregulation of u-PAR through a PEA3/ets tran-
scriptional silencing element. Knowledge of the mo-
lecular regulation of this molecule in tumor cells
could be very important for diagnosis and therapy in
the near future.
Key words: Cancer /Transcription /Tumor-associated
proteolysis /u-PAR.
Introduction
The phenomenon of tumor-associated proteolysis has
been acknowledged as a decisive step in cancer pro-
gression, invasion and metastasis. One of the proteases
which has been implicated in the invasive phenotype of
tumor cells is the urokinase-type plasminogen activator
(u-PA), a 55 kDa serine protease which, via activation of
plasminogen to active plasmin, is able to cleave several
components of the extracellular matrix including fibrin, fi-
bronectin, proteoglycans and, as the main molecules in
basement membranes, laminin and collagen IV (Duffy,
1992). u-PA interacts with factors often summarized as
the plasminogen activator system, consisting of the en-
zyme (u-PA), one substrate (plasminogen), two receptors
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actions, and modulate transduction of regulatory signals
that are central to inflammation, immunity, hemostasis,
and tumor progression. u-PAR physically interacts on
leukocytes with β2-integrin (Bohuslav et al., 1995), and
on fibrosarcoma cells with β1- and β3-integrins (Xue
et al., 1997). Current evidence favors a model in which
ligand-induced integrin clustering, a central event in inte-
grin activation, promotes caveolin oligomerization lead-
ing to release and/or activation of Src-family kinases and
initiation of integrin signaling. The presence of u-PAR
promotes these events because the extracellular domain
of u-PAR binds to β1- and β2-integrins, and the GPI an-
chor of u-PAR, like that of other GPI-anchored proteins,
interacts with cholesterol-rich membrane domains en-
riched in caveolin and tyrosine kinases (Chapman et al.,
1999). Fourth, the u-PAR is chemotactic for human
monocytes and mast cells, and this may contribute to in-
flammatory and tissue remodeling processes, which are
also often observed in tumor-infiltrated areas (Resnati
et al., 1996; Sillaber et al., 1997).
The Relevance of u-PAR Gene Expression to
Invasion and Metastasis
Numerous studies have shown an overexpression of the
u-PAR gene in diverse human malignant tumors in con-
trast to the corresponding normal tissue and/or sur-
rounding stromal cells (Pyke et al., 1991a,b; Jankun 
et al., 1993; Morita et al., 1998) and suggested u-PAR as
a characteristic of the invasive or even the malignant
phenotype (Hollas et al., 1991; Bianchi et al., 1994; Wang
et al., 1994). Further studies demonstrated u-PAR and
the plasminogen activator system to be strong and inde-
pendent parameters predicting a poor prognosis of can-
cer patients (Duffy et al., 1990; Jaenicke et al., 1993) suf-
fering from lung (Pedersen et al., 1994), colon (Mulcahy
et al., 1994; Ganesh et al., 1994), esophageal and gastric
carninoma (Allgayer et al., 1998; Nekarda et al., 1998).
Duffy et al. (2002) showed that breast cancer patients
with high u-PA activity in their primary tumors had a
shorter disease-free interval than patients with low u-PA
activity.
Experimental evidence implicating u-PAR in tumor in-
vasion and metastasis are as follows: overexpression of a
human u-PAR cDNA increased the ability of human os-
teosarcoma cells to penetrate a barrier of reconstituted
basement membrane (Kariko et al., 1993). Ossowski
(1988) demonstrated that the invasive potential of tumor
cells into a chicken embryo chorioallantoic membrane is
correlated with u-PAR-associated proteolytic activity.
Another study (Kook et al., 1994) revealed that the ex-
pression of an antisense u-PAR cDNA in Hep3 squamous
carcinoma cells decreased their invasiveness into a mod-
ified chorioallantoic membrane. Furthermore, antisense
oligonucleotides inhibiting u-PAR gene expression re-
duced in vitro invasion of transformed human fibroblasts
(Quattrone et al., 1995). In glioblastoma, an anti-u-PAR
monoclonal antibody effectively blocked matrigel inva-
sion of treated cells (Mohanam et al., 1993). In cultured
human lung cancer cell lines, optimum invasiveness was
seen only if u-PA, PAI-1 and u-PAR were co-expressed
(Liu et al., 1995). High concentrations of PAI-1 also corre-
late with poor prognosis in patients with breast cancer,
including the subgroup with node-negative disease. Pos-
sible mechanisms by which PAI-1 contributes to cancer
dissemination include modulating cellular adhesion and
migration, playing a role in angiogenesis, and stimulating
cell proliferation (Duffy et al., 2002). Moreover, Kim et al.
(1998) have shown elegantly that the expression of the u-
PAR gene by tumor cells, besides u-PA and MMP-9, is re-
quired for the intravasation of blood vessels. Min et al.
(1996) reported that u-PAR antagonists prevent tumor
growth and angiogenesis, suggesting that u-PAR gene
expression is important for tumor and metastasis estab-
lishment and outgrowth. Finally, Lakka et al. (2001) re-
ported that the transfection of an adenovirus construct
(Ad-uPAR) in non-small cell lung cancer cell lines with
high levels of u-PAR resulted in a decrease of u-PAR lev-
els by 80 – 90% , leading to a reduction of invasion and
metastasis. Taken together, all of these studies suggest
u-PAR as a critical molecule for invasion, intravasation,
and metastasis. 
Transcriptional Activation of u-PAR Gene
Expression
The objective to counter u-PAR gene expression in ma-
lignant tumors necessarily implies the question as to how
it is regulated. The mechanisms of regulation and causes
for an upregulation of u-PAR in malignant cells are still the
objectives of intensive investigations. Although altered
mRNA stability and receptor recycling may be involved,
the amounts of u-PAR are controlled mainly at the tran-
scriptional level in malignancies such as colon cancer
(Lund et al., 1995; Lengyel et al., 1996; Shetty et al., 1997;
Gum et al., 1998). Altered transcription of the gene is the
main mediator of u-PAR gene expression brought about
by, for example, epidermal growth factor (EGF; Boyd,
1989), basic fibroblast growth factor (FGF; Mignatti et al.,
1991), vascular endothelial growth factor (VEGF; Mandri-
ota et al., 1995), transforming growth factor β type 1
(TGF-β1; Lund et al., 1995), phorbol 12-myristate 13-ac-
etate (PMA; Lengyel et al., 1996), IFN-α or IFN-γ, (Wu
et al., 2002), protein kinase C (PKC; Ando et al., 1996),
protein kinase A (PKA)/c-AMP (Langer et al., 1993; Li
et al., 1995), the MAPK- (Lengyel et al., 1997) and the
JNK-pathway (Gum et al., 1998).
The u-PAR gene spans seven exons and is located on
chromosome 19q13 (Borglum et al., 1992). Transcription
of the gene yields a 1.4 kb mRNA or an alternatively
spliced variant lacking the membrane attachment pep-
tide sequence (Roldan et al., 1990; Pyke et al., 1993). The
human u-PAR promoter sequence was first described by
Wang et al. (1995) and Soravia et al. (1995). Like classic
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‘housekeeping genes’, it lacks TATA and CAAT boxes and
contains a GC-rich proximal sequence with multiple Sp1
consensus elements. Using primer extension analysis,
Soravia et al. (1995) reported three transcriptional start
sites, the most upstream of which – an A following a C –
appeared to be the main transcription initiation site and
revealed partial similarity to the consensus initiator se-
quence of the dihydrofolate reductase (DHFR) gene
(Means et al., 1990; Soravia et al., 1995). The most prox-
imal 135 base pairs of the human u-PAR promoter
showed 68% similarity to the murine u-PAR promoter
(Suh et al., 1994).
An overview on the current status on putative or ex-
perimentally validated promoter elements regulating the
u-PAR gene is given in Figure 1.
First reports of Soravia et al. (1995) suggested that the
basal expression of the gene is regulated via Sp1 motifs
proximal and upstream of the transcriptional start site. In
colon cancer, both the constitutive and PMA-inducible
expression of the gene required a footprinted region lo-
cated at basepairs -190/-171 of the promoter containing
an AP-1 consensus motif bound by Jun-D, c-Jun, c-Fos
and Fra-1 (Lengyel et al., 1996). This motif also mediates
the induction of u-PAR gene expression via the MAPK-
and the JNK-pathway (Lengyel et al., 1997; Gum et al.,
1998).
This AP-1 consensus motif is also required for induc-
tion of u-PAR gene expression brought about by the
K-ras oncogene (Allgayer et al., 1999). A substantial re-
duction of endogenous u-PAR protein and u-PAR-medi-
ated proteolysis was observed in HCT116 clones in
which activated K-ras had been deleted. In gelshift and
CAT-reporter analysis we detected a decrease of the
binding of c-Jun, JunD, c-Fos and Fra-1 in the K-ras-
knockout clones, and this was paralleled by a severe re-
duction of promoter activity when the AP-1-consensus
motif within promoter region -190/-171 was deleted.
These results suggest that activated K-ras regulates
u-PAR and u-PAR-mediated proteolysis in colon cancer,
at least in part via the -190/-171 region of the promoter
bound by AP-1-transcription factors.
Ras uses a variety of functionally diverse effectors that
transduce signals through multiple pathways. The bind-
ing of effector proteins involves at least interactions with
the effector loop (amino acids 32 – 40) of Ras. The use of
multiple effector pathways by Ras has been demonstrat-
ed through the use of constitutively activated mutants of
Ras with point mutations in the effector domain. Muller
et al. (2000) showed that constitutively active V12 H-Ras
and Rho-A lead to an increased transcription from the u-
PAR promoter. Thereby the use of Ras-effector-loop mu-
tants indicated that signaling via multiple Ras effectors is
necessary for the maximum activation of u-PAR tran-
scription. Okan et al. (2001) further showed that a consti-
tutively activated RalA mutant (RalA 72L) stimulates u-
PAR transcription. RalA is one of two highly similar (85%
identity) GTPases of the Ras subfamily. The stimulation of
u-PAR transcription required the presence of the ATF2-
like AP-1 site at 70 bp and the c-Jun binding motif at -
184 bp upstream of the major transcriptional start site.
Activation of transcription is inhibited by a dominant-
negative mutant of c-Src, indicating that c-Src is a down-
stream effector of RalA. These data showed activation of
u-PAR trancription by RalA through an AP-1-dependent
mechanism.
Another footprinted region (-148/-124) of the u-PAR-
promoter containing putative binding sites for (mis-
matched) Sp1, AP-2 and PEA3 binding motifs (Lengyel
et al., 1996) was shown to be bound by an AP-2α-like
protein closely related to, but not identical with, authentic
AP-2α, Sp1 and Sp3 transcription factors. The region re-
quired for binding were identified as -152/-135 (Allgayer
et al., 1999a). Binding of the AP-2α-like protein was
found to be important for a constitutively high u-PAR pro-
moter activity in a highly invasive colon cancer cell line
and for PMA-stimulated u-PAR expression in a cell line
with low constitutive u-PAR expression. Interestingly, a
dominant-negative AP-2 expression construct not only
reduced u-PAR promoter activity and u-PAR gene ex-
pression but also substantially inhibited u-PAR-mediated
proteolysis. These results suggest that an inhibition at the
transcriptional level can be used to suppress u-PAR-me-
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diated proteolysis, thereby potentially inhibiting invasion
and metastasis. 
The binding of Sp1 transcription factor to region -152/-
135 of the u-PAR promoter was shown to be important in
part for PMA-induced u-PAR promoter activity, but, more
interestingly, for the induction of u-PAR gene expression
by the c-src oncogene in colon cancer (Allgayer et al.,
1999b). In SW480 colon cancer clones stably expressing
a constitutively active Src (Y-c-src527F), increased u-
PAR protein and laminin degradation paralleling elevated
Src activity was evident as compared to parental cells.
Nuclear run-on experiments indicated that the increased
u-PAR protein was due largely to transcriptional activa-
tion. While transient transfection of SW480 cells with 
Y-c-src527F induced a u-PAR-CAT-reporter, mutations
preventing Sp1-binding to promoter region -152/-135
abolished this induction. Mobility shift assays revealed
increased Sp1 binding to region -152/-135 with nuclear
extracts of Src-transfected SW480 cells. Finally, the
amounts of endogenous u-PAR in resected colon can-
cers significantly correlated with Src-activity. These data
suggest that u-PAR gene expression and u-PAR-mediat-
ed proteolysis are regulated by Src, which requires the
promoter region (-152/-135) bound by Sp1, thus demon-
strating for the first time that transcription factor Sp1 is a
downstream effector of Src.
The transcription factor NF-κB has also been implicat-
ed in the regulation of the u-PAR. In a recent study, Wang
et al. (2000) implicated NF-κB bound to a non-consensus
NF-κB motif (-51/-30) in the constitutive expression of
the u-PAR gene in HCT116 colon cancer cells. Co-trans-
fection with a dominant-negative IκB-kinase-2 expres-
sion vector reduced u-PAR promoter activity up to 75%,
demonstrating that this region is required for promoter
activity. 
Transcriptional Downregulation of u-PAR
Although many reports showed a transcriptional activa-
tion of u-PAR gene expression by diverse promoter mo-
tifs, there is not much known about potential silencer el-
ements. One example for transcriptional suppression has
been given by Hapke et al. (2001), indicating a PEA3-ele-
ment at -248 bp as a mediator of integrin-induced sup-
pression: the adhesion receptor β3-integrin downregulat-
ed u-PAR in CHO cells, an overexpression of β3-integrin
leading to a reduction of u-PAR mRNA and u-PAR pro-
moter activity. Downregulation of u-PAR expression can
be increased by clustering of αvβ3-integrin, which was
achieved after ligation with immobilized vitronectin or the
antibody LM609. After transient transfection, a CAT re-
porter driven by 398 bp of 5’-flanking sequence of the u-
PAR promoter was significantly reduced by a β3-integrin
expression construct, whereas transfection of αv-inte-
grin alone did not show any effect on the u-PAR promot-
er. This indicated that the u-PAR promoter contains a
transcription factor binding site that might account for a
β3-integrin-mediated repression of u-PAR gene tran-
scription in CHO cells. Using 5’-deletion fragments of the
u-PAR promoter and the β3-integrin expression vector, a
sequence between -398 and -197 bp of the u-PAR pro-
moter was identified to be essential for β3-integrin-medi-
ated u-PAR gene suppression. Deletion of the PEA3/ets
motif at position -248 prevented the ability of β3-integrin
to downregulate the u-PAR promoter. Furthermore, an
expression vector encoding PEA3 inhibited the activity of
the wild type but not the activity of the mutated form. In
β3-integrin-overexpressing cells, nuclear factors showed
enhanced binding activity for the PEA3/ets site and PEA3
was identified by an anti-PEA3 antibody which inhibited
DNA-protein complex formation. These experiments
suggest a PEA3/ets motif at -248 bp as a transcriptional
repressor of the u-PAR gene (Hapke et al., 2001).
Recently, a new tumor suppressor gene (pdcd4) in-
hibiting neoplastic transformation of epithelial cells has
been identified, however, its role in invasion and mecha-
nisms of regulation has not been investigated yet (Cmarik
et al., 1999; Hsu et al., 2000; Yang et al., 2001). Prelimi-
nary studies of our group implicate that Pdcd4 might
downregulate u-PAR gene expression at least in part by
inhibiting u-PAR gene transcription, and a region contain-
ing putative binding sites for Sp-1, GATA-2 and NF-1
(-402/-350 bp), but also the PEA3/ets motif at -248 bp
might be mediators of this suppression (Leupold et al.,
2002) 
Conclusion
In summary, the u-PAR is a central molecule of invasion
and metastasis with clinical-prognostic value that has
been shown to be regulated especially at the transcrip-
tional level by diverse cis-elements and trans-acting fac-
tors. These mediate multiple means of induction or sup-
pression by different regulators involving, for example,
signaling cascades, oncogenes, or even potentially tu-
mor suppressor genes. When speculating about devel-
oping future therapeutic strategies based on this knowl-
edge, it is interesting to hypothesize that, besides already
existing u-PAR-inhibitory strategies at the protein level
(antibodies, small molecular compounds; Wilhelm et al.,
1994; Renatus et al., 1998; Aguirre-Ghiso et al., 1999) or
efforts to inhibit at the signal transduction level (e.g.
MAPK-, Src- and K-Ras-inhibition) even a direct targeting
of transcriptional mechanisms could be considered.
To support this notion, in a first clinical study compar-
ing transcription factor binding to u-PAR promoter region
-152/-135 in 145 patients with resected colorectal or gas-
tric cancers in primary tumors and corresponding normal
mucosae, we suggested a tumor-specific transactivation
of u-PAR gene expression by this promoter region in
about 60% of cases (Schewe et al., 2001). Therefore, it
might be possible in the future to identify subgroups of
patients where a targeting of certain promoter regions
with a preference for tumor cells could be speculated. It
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should be attractive to further develop targeting methods
such as triplex binding oligonucleotides which might be
appropriate to be applied as targeting tools at the tran-
scriptional level.
Ultimately, there is to be expected an exciting devel-
opment in next few years to extend the knowledge on u-
PAR and its regulators as molecular markers to improve
the prediction of an individual patient’s clinical outcome,
define approaches in the treatment of cancer invasion
and metastasis, and define appropiate target subpopula-
tions of patients.
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